Centro de Investigação em Ciências da Saúde, Universidade da Beira Interior (CICS-UBI), 6200-506 Covilhã, Portugal.
Laboratório de Fármaco-Toxicologia, UBIMedical, Universidade da Beira Interior, EM506, 6200-000 Covilhã, Portugal.
Int J Mol Sci. 2024 May 29;25(11):5925. doi: 10.3390/ijms25115925.
This review emphasises the importance of opioid monitoring in clinical practice and advocates for a personalised approach based on pharmacogenetics. Beyond effectively managing pain, meticulous oversight is required to address concerns about side effects, specially due to opioid-crisis-related abuse and dependence. Various monitoring techniques, along with pharmacogenetic considerations, are critical for personalising treatment and optimising pain relief while reducing misuse and addiction risks. Future perspectives reveal both opportunities and challenges, with advances in analytical technologies holding promise for increasing monitoring efficiency. The integration of pharmacogenetics has the potential to transform pain management by allowing for a precise prediction of drug responses. Nevertheless, challenges such as prominent pharmacogenetic testing and guideline standardisation persist. Collaborative efforts are critical for transforming scientific advances into tangible improvements in patient care. Standardised protocols and interdisciplinary collaboration are required to ensure consistent and evidence-based opioid monitoring. Future research should look into the long-term effects of opioid therapy, as well as the impact of genetic factors on individual responses, to help guide personalised treatment plans and reduce adverse events. Lastly, embracing innovation and collaboration can improve the standard of care in chronic pain management by striking a balance between pain relief and patient safety.
这篇综述强调了在临床实践中进行阿片类药物监测的重要性,并倡导基于药物遗传学的个体化方法。除了有效管理疼痛外,还需要细致的监督来解决副作用的问题,特别是由于阿片类药物危机相关的滥用和依赖。各种监测技术,以及药物遗传学的考虑因素,对于个性化治疗和优化疼痛缓解至关重要,同时降低误用和成瘾的风险。未来的展望既带来了机遇也带来了挑战,分析技术的进步为提高监测效率提供了可能。药物遗传学的整合具有通过精确预测药物反应来改变疼痛管理的潜力。然而,仍然存在一些挑战,如突出的药物遗传学测试和指南标准化问题。协作努力对于将科学进步转化为患者护理的实际改进至关重要。需要制定标准化的方案和开展跨学科合作,以确保阿片类药物监测的一致性和基于证据。未来的研究应关注阿片类药物治疗的长期效果,以及遗传因素对个体反应的影响,以帮助指导个体化治疗计划并减少不良事件。最后,通过创新和合作来平衡疼痛缓解和患者安全,可以提高慢性疼痛管理的护理标准。